NCT04734990View on ClinicalTrials.gov

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 7, 2021

Primary Completion Date

September 11, 2027

Study Completion Date

September 11, 2027

Conditions

Chronic Myelomonocytic Leukemia-0Chronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2Myelodysplastic SyndromeRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome

Interventions

DRUG

Azacitidine

Given IV or SC

DRUG

Seclidemstat

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER